论文部分内容阅读
目的观察利妥昔单抗(rituximab,商品名美罗华)联合方案化疗治疗B淋巴细胞性恶性肿瘤的疗效、安全性及毒副反应。方法回顾性分析2000年12月至2005年03月采用美罗华单药或联合化疗对22例B淋巴细胞性恶性肿瘤患者的疗效、安全性及毒副反应。结果治疗后,7例(31.8%)完全缓解(CR),8例(36.4%)部分缓解(PR),3例(13.6%)病情稳定(SD)及4例(18.2%)病情进展(PD)。结论美罗华治疗B淋巴细胞性恶性肿瘤疗效较为显著,且毒副反应较轻。
Objective To observe the efficacy, safety and toxicity of rituximab (Rituximab) combined with chemotherapy in the treatment of B lymphocytic malignancies. Methods Retrospective analysis of the efficacy, safety and toxicity of 22 patients with B lymphocytic malignancies treated with rituximab or combination chemotherapy from December 2000 to March 2005 were retrospectively analyzed. Results After treatment, complete remission was achieved in 7 patients (31.8%), partial remission in 8 patients (36.4%), stable disease (SD) in 3 patients (13.6%) and progression of the disease in 4 patients (18.2%) ). Conclusion Rituximab treatment of B lymphocytic malignancies more effective, and less toxic side effects.